10x Genomics Inc [TXG] stock prices are up 7.46% to $22.05 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TXG shares have gain 11.36% over the last week, with a monthly amount glided 40.00%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
10x Genomics Inc [NASDAQ: TXG] stock has seen the most recent analyst activity on December 11, 2025, when Citigroup downgraded its rating to a Neutral. Previously, Morgan Stanley downgraded its rating to Equal-Weight on December 02, 2025, and kept the price target unchanged to $20. On September 11, 2025, Piper Sandler initiated with a Neutral rating and assigned a price target of $15 on the stock. Leerink Partners downgraded its rating to a Market Perform and decreased its price target to $12 on February 13, 2025. Leerink Partners initiated its recommendation with a Outperform and recommended $35 as its price target on September 03, 2024. Jefferies upgraded its rating to Buy for this stock on July 22, 2024, but kept the price target unchanged to $24. In a note dated July 18, 2024, JP Morgan downgraded an Neutral rating on this stock and revised its target price from $40 to $20.
The stock price of 10x Genomics Inc [TXG] has been fluctuating between $6.78 and $21.50 over the past year. Currently, Wall Street analysts expect the stock to reach $18.33 within the next 12 months. 10x Genomics Inc [NASDAQ: TXG] shares were valued at $22.05 at the most recent close of the market. An investor can expect a potential drop of -16.87% based on the average TXG price forecast.
Analyzing the TXG fundamentals
The 10x Genomics Inc [NASDAQ:TXG] reported sales of 641.81M for trailing twelve months, representing a drop of -1.75%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.14%, Pretax Profit Margin comes in at -0.11%, and Net Profit Margin reading is -0.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.1 and Total Capital is -0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that 10x Genomics Inc [NASDAQ:TXG]’s Current Ratio is 4.48. Also, the Quick Ratio is 4.06, while the Cash Ratio stands at 2.94. Considering the valuation of this stock, the price to sales ratio is 4.35, the price to book ratio is 3.55.
Transactions by insiders
Recent insider trading involved Taich Adam, Chief Financial Officer, that happened on Nov 24 ’25 when 11888.0 shares were sold. See Remarks, Hindson Benjamin J. completed a deal on Nov 24 ’25 to sell 8283.0 shares. Meanwhile, Chief Executive Officer Saxonov Serge sold 13261.0 shares on Nov 24 ’25.
